60 results
Page 2 of 3
8-K
5yi2s 9dkg3ja1bajm2
3 Dec 21
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
7:45am
8-K
EX-99.1
vfs8ajqgbrb1a3oem
22 Nov 21
Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
7:40am
8-K
EX-99.1
n5b87l xam
19 Oct 21
Zai Lab and Entasis Therapeutics Announce Positive
9:21am
10-Q
qml9gc v09mo65hp3ac
10 May 21
Quarterly report
8:58am
DEF 14A
f16yzfpp0actf6g1 4i
30 Apr 21
Definitive proxy
4:02pm
424B5
swyuc8tw3yase263
21 Apr 21
Prospectus supplement for primary offering
4:45pm
424B5
2r3a psim5jgvc6oh
19 Apr 21
Prospectus supplement for primary offering
4:57pm
S-3ASR
8d0k i0gtu42gqq
19 Apr 21
Automatic shelf registration
4:11pm
PRE 14A
hx8082 7bs64xkml3ou
14 Apr 21
Preliminary proxy
4:00pm
8-K
EX-99.1
hy7 chzis
31 Mar 21
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal
7:32am
8-K
EX-99.1
ejiy6m91gunirthos91
1 Mar 21
Zai Lab Announces Financial Results
7:01am
10-K
EX-10.20
ig0w0c
1 Mar 21
Annual report
12:00am
10-K
ojztce 1qhbry8
1 Mar 21
Annual report
12:00am
6-K
EX-99.1
epcq940srv2zpt161iy3
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
EX-99.1
ytysw0ebr v912
11 Sep 20
Current report (foreign)
8:16am
6-K
EX-99.1
e1ovm
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
t7bucuf
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am